版本:
中国

BRIEF-Amgen and Cytokinetics say Lancet published results from Phase 2 clinical trial evaluating omecamtiv mecarbil

Nov 30 Cytokinetics Inc

* Says Amgen and co announced Lancet published results from a Phase 2 clinical trial evaluating omecamtiv mecarbil

* Cytokinetics - statistically significant improvements in all pre-specified secondary measures

* Cytokinetics Inc says Adverse Events (AES), including serious AES, in patients on omecamtiv mecarbil were comparable to placebo Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐